The Beneficial and Detrimental Effects of Prolactin Hormone on Metabolic Syndrome: A Double-edge Sword

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2024 Dec 12

PMID 39663784

Authors

Ayah Talal Zaidalkilani

Hayder M Al-Kuraishy

Ali I Al-Gareeb

Athanasios Alexiou

Marios Papadakis

Ammar Al-Farga

Othman A Alghamdi

Mostafa M Bahaa

Mohammed Alrouji

Mohammed S Alshammari

Gaber El-Saber Batiha

Affiliations

Soon will be listed here.

Abstract

The metabolic syndrome (MetS) is a clustering of abdominal obesity, hypertension, hyperglycaemia, hypertriglyceridemia and low high-density lipoprotein (HDL) level. MetS development is affected by endocrine hormones such as prolactin (PRL) hormone which induce insulin resistance and central obesity because PRL is implicated in the pathogenesis of MetS. Pituitary PRL controls mammary gland, however extra-pituitary PRL is highly intricate in the regulation of adipose tissue function. In addition, cAMP activators enhance expression and release of PRL which involved in the control of lipogenesis and energy homeostasis. Consequently, hyperprolactinaemia may be associated with the development of MetS. However, normal physiological level of PRL is essential for insulin sensitivity and regulation of adipose tissue function and energy metabolism. Therefore, PRL has dual effects on the components of MetS. Hence, the present review aims to discuss the modulatory mechanistic role of PRL on MetS regarding its beneficial and detrimental effects.

References

Baptista T, de Baptista E, Lalonde J, Plamondon J, Ng Ying Kin N, Beaulieu S . Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(8):1305-11. DOI: 10.1016/j.pnpbp.2004.08.001. View

Phillips G . Sex hormones, risk factors and cardiovascular disease. Am J Med. 1978; 65(1):7-11. DOI: 10.1016/0002-9343(78)90685-x. View

Ni Y, Ni L, Zhuge F, Xu L, Fu Z, Ota T . Adipose Tissue Macrophage Phenotypes and Characteristics: The Key to Insulin Resistance in Obesity and Metabolic Disorders. Obesity (Silver Spring). 2020; 28(2):225-234. DOI: 10.1002/oby.22674. View

Wagner R, Heni M, Linder K, Ketterer C, Peter A, Bohm A . Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans. Acta Diabetol. 2013; 51(1):71-8. DOI: 10.1007/s00592-013-0493-7. View

Xu S, Zhang X, Liu S, Feng S, Xiang G, Xu C . Multi-Omic Analysis in a Metabolic Syndrome Porcine Model Implicates Arachidonic Acid Metabolism Disorder as a Risk Factor for Atherosclerosis. Front Nutr. 2022; 9:807118. PMC: 8906569. DOI: 10.3389/fnut.2022.807118. View

Prazienkova V, Popelova A, Kunes J, Maletinska L . Prolactin-Releasing Peptide: Physiological and Pharmacological Properties. Int J Mol Sci. 2019; 20(21). PMC: 6862262. DOI: 10.3390/ijms20215297. View

Banerjee R, Cyphert H, Walker E, Chakravarthy H, Peiris H, Gu X . Gestational Diabetes Mellitus From Inactivation of Prolactin Receptor and MafB in Islet β-Cells. Diabetes. 2016; 65(8):2331-41. PMC: 4955982. DOI: 10.2337/db15-1527. View

Park S, Kim D, Daily J, Kim S . Serum prolactin concentrations determine whether they improve or impair β-cell function and insulin sensitivity in diabetic rats. Diabetes Metab Res Rev. 2011; 27(6):564-74. DOI: 10.1002/dmrr.1215. View

Hirode G, Wong R . Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. JAMA. 2020; 323(24):2526-2528. PMC: 7312413. DOI: 10.1001/jama.2020.4501. View

10.

Chan K, Cathomas F, Russo S . Central and Peripheral Inflammation Link Metabolic Syndrome and Major Depressive Disorder. Physiology (Bethesda). 2019; 34(2):123-133. PMC: 6586832. DOI: 10.1152/physiol.00047.2018. View

11.

Bosch I Ara L, Katugampola H, Dattani M . Congenital Hypopituitarism During the Neonatal Period: Epidemiology, Pathogenesis, Therapeutic Options, and Outcome. Front Pediatr. 2021; 8:600962. PMC: 7902025. DOI: 10.3389/fped.2020.600962. View

12.

Lorenzo C, Williams K, Hunt K, Haffner S . The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2006; 30(1):8-13. DOI: 10.2337/dc06-1414. View

13.

Shimmura M, Takase K . Clinical utility of serum prolactin and lactate concentrations to differentiate epileptic seizures from non-epileptic attacks in the emergency room. Seizure. 2022; 95:75-80. DOI: 10.1016/j.seizure.2021.12.014. View

14.

Fahed G, Aoun L, Zerdan M, Allam S, Zerdan M, Bouferraa Y . Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022; 23(2). PMC: 8775991. DOI: 10.3390/ijms23020786. View

15.

Chan S, Selemidis S, Bozinovski S, Vlahos R . Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther. 2019; 198:160-188. PMC: 7112632. DOI: 10.1016/j.pharmthera.2019.02.013. View

16.

Corbacho A, de la Escalera G, Clapp C . Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol. 2002; 173(2):219-38. DOI: 10.1677/joe.0.1730219. View

17.

Glintborg D, Altinok M, Mumm H, Buch K, Ravn P, Andersen M . Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. Hum Reprod. 2014; 29(8):1773-9. DOI: 10.1093/humrep/deu133. View

18.

Bovolini A, Garcia J, Andrade M, Duarte J . Metabolic Syndrome Pathophysiology and Predisposing Factors. Int J Sports Med. 2020; 42(3):199-214. DOI: 10.1055/a-1263-0898. View

19.

Luzardo-Ocampo I, Ocampo-Ruiz A, Dena-Beltran J, Martinez de la Escalera G, Clapp C, Macotela Y . The Diversity of Gut Microbiota at Weaning Is Altered in Prolactin Receptor-Null Mice. Nutrients. 2023; 15(15). PMC: 10420910. DOI: 10.3390/nu15153447. View

20.

Al-Kuraishy H, Al-Gareeb A, Elekhnawy E, El-Saber Batiha G . Possible role of LCZ696 in atherosclerosis: new inroads and perspective. Mol Cell Biochem. 2023; 479(8):1895-1908. DOI: 10.1007/s11010-023-04816-x. View